Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Kendra L. Sweet, MD, Naveen Pemmaraju, MD, Andrew A Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Eric K. Rowinsky, MD, Michael Szarek, PhD, Christopher L. Brooks, PhD, Sarah Disalvatore, MPH, David Liu, Madeleine Duvic, MD, Jonathan D. Schwartz, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3795.

https://doi.org/10.1182/blood.V126.23.3795.3795

Published: 2015

Journal Articles

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Janice Chen, PhD, Christopher L. Brooks, PhD, Peter McDonald, Jonathan D. Schwartz, MD, Rebecca S. Schneider, Keiichi Sakakibara, PhD, Naoya Saito, PhD, Takuji Sato, MSc, Takumi Kawabe, MD PhD, Eric K. Rowinsky, MD

Blood (2015) 126 (23): 4433.

https://doi.org/10.1182/blood.V126.23.4433.4433

Published: 2015

Journal Articles

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

Arghya Ray, PhD, Deepika Sharma DAS, PhD, Yan Song, PhD, Vincent Macri, MA, Christopher L. Brooks, PhD, Eric K. Rowinsky, MD, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 3000.

https://doi.org/10.1182/blood.V126.23.3000.3000

Published: 2015

Journal Articles

A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea

Gladys I. Rodriguez, John G. Kuhn, Geoffrey R. Weiss, Susan G. Hilsenbeck, John R. Eckardt, Allison Thurman, David A. Rinaldi, Stephanie Hodges, Daniel D. Von Hoff, Eric K. Rowinsky

Blood (1998) 91 (5): 1533–1541.

https://doi.org/10.1182/blood.V91.5.1533

Published: 1998

Journal Articles

Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells

Scott H. Kaufmann, Phyllis A. Svingen, Steven D. Gore, Deborah K. Armstrong, Yung-Chi Cheng, Eric K. Rowinsky

Blood (1997) 89 (6): 2098–2104.

https://doi.org/10.1182/blood.V89.6.2098

Published: 1997

NARROW

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea

Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea

Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only